drugset / Trial / NCT01719380
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
Timeline
- Start
- 2012-11-23
- Primary completion
- 2015-10-31
- Completion
- 2019-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpelisib | Small molecule | — | — |
| Subject | Encorafenib | Small molecule | — | — |
| Background | Cetuximab | Monoclonal antibody | — | — |